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Hospitalised patients are at high risk of loss of muscle mass and function as a consequence 
of a period of immobilisation, due to fractures or other conditions requiring surgery or 
critical care. These adverse outcomes can be attenuated by resistance exercise but 
performing and adhering to the required exercise programme can be challenging and 
difficult for this population. The technique of neuromuscular electrical stimulation (NMES) 
may be employed as an alternative to exercise in preventing or reversing the loss of muscle 
mass and/or function. 
 
Objective 
To examine the evidence for the effects of NMES applied to one or more limbs in acutely 
hospitalised adult patients. 
 
Method 
MEDLINE, EMBASE, Cumulative Index to Nursing & Allied Health (CINAHL) and the 
Cochrane library will be searched for relevant studies. Inclusion criteria: randomized 
controlled trials (RCTs) of hospitalised adult patients (aged ≥ 18 years) comparing NMES 
alone or with other interventions to usual care or other interventions. Our primary outcome 
of interest is muscle strength, and our secondary outcomes include but not limited to the 
following outcomes and categories: muscle mass, molecular and cellular function, hospital 
length of stay and adverse effects. Two reviewers will independently screen the titles and 
abstracts, then full texts against the eligibility criteria. Data extraction, critical appraisal 
and synthesis will be conducted using Review Manager (RevMan) software. Quality of 
evidence and rating will be assessed by the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) tool.  Meta-analysis will be conducted where 
possible, otherwise a synthesis without meta-analysis will be conducted, based upon the 
volume of evidence, its quality and effect sizes observed.    
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The loss of muscle mass and function associated with ageing is known as sarcopenia. Rapid 
loss of mass and function can be observed in adults hospitalised with acute conditions such 
as fractures, acute respiratory diseases, heart failure, kidney dysfunction or any condition 
requiring surgery or critical care – this is often referred to as secondary sarcopenia [1] 
and may be due to immobilisation, inflammation and dietary inadequacies [2]. Secondary 
sarcopenia can lead to the limitations in activities, called hospital-associated disability [3], 
and this can lead to an extended length of hospital stay, health risks due to disability itself 
and, potentially, long term disability. Early physical activity and mobilisation play an 
essential role in acute care, aiming to prevent this cascade of consequences [4].  
 
The effects of exercise on muscle mass and function in hospitalised patients have been 
extensively investigated. Improvement in activities of daily living, walking, health-related 
quality of life, and muscle strength have been observed in patients hospitalised for chronic 
obstructive respiratory disease after a period of combined exercise/rehabilitation 
(stretching, resistance, and aerobic exercises) [5] and resistance exercise alone [6]. 
Additionally, increase in muscle mass after whole body heavy resistance exercise has been 
detected in hospitalized patients on geriatric medicine wards [7]. Despite the promising 
effects of exercise, the implementation of such protocols can be challenging because 
patients who are hospitalised may be medically unstable or receiving therapy [8]. 
Furthermore, the reasons for admission to hospital can include pain, immobilisation, 
fatigue and cardio-respiratory symptoms, which can both be barriers to exercise and 
counted as adverse events in hospitalised patients who have been prescribed exercise 
interventions [9]. Therefore, alternative techniques should be explored, instead of or in 
addition to exercise, to mitigate against loss of muscle mass and function acquired after 
hospitalisation. 
 
Neuromuscular Electrical Stimulation (NMES) is a technology that enables involuntary 
muscle contraction using non-invasive, low-frequency current, and can be performed with 
or without voluntary effort [10]. NMES parameters includes frequency (Hz), pulse duration 
(microseconds, μs), pulse amplitude (millivolts or milliamperes), work-rest cycle (ON:OFF 
ratio), session duration (min), session frequency (days/week) [10]. Pilot searches 
conducted by Alqurashi in 2021 searching Medline for systematic reviews and NMES 
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identified 88 separate review articles, concerning many different biological, muscular and 
functional outcomes, in different populations (children, adults, athletes, old adults) and in 
both healthy volunteers and patients with a variety of conditions. These reviews examined 
the effect of NMES on patients with neurological disorders (stroke, spinal cord injury) [11, 
12], knee osteoarthritis and arthroplasty [13, 14], chronic obstructive respiratory disease 
[15], heart failure [16], cancer [17], kidney failure [18], swallowing [19], speech [20] and 
oedema [21]. There were two reviews focussed upon critically ill hospitalised patients [22, 
23]. Another review focused on interventions for secondary sarcopenia in older people in 
hospital [24], which included three studies on the use of NMES. No review was found 
specifically focussed upon the effects of NMES to maintain or restore limb function in adults 
admitted to hospital with acute conditions. However, a protocol for such a review on the 
PROSPERO database of systematic reviews [25] was identified. This systematic review, 
like the one listed on the PROSPERO database, aims to examine the evidence of the effects 
of NMES applied to one or more limbs in acutely hospitalised adult patients. In comparison 
with the registered review, this review will include NMES together with other interventions 
and for the comparator arm, this review will include other non-placebo comparator groups 
(e.g. usual care including exercise or nutrition). Further, this review will include a broad 
range of outcomes and a broader range of study publication dates. 
 
METHOD 
This protocol was written in accordance with the PRISMA-P reporting guideline [26], and 
it has been registered at the International Prospective Register of Systematic Reviews 
(PROSPERO; registration number: CRD42021259763). 
Eligibility criteria 
Inclusion criteria 
• Participants: adults and older adults (aged ≥ 18 years) who are admitted to hospital 
with acute medical or surgical conditions. 
• Intervention: NMES applied to a limb alone or combined with different 
interventions. 
• Control: no treatment, sham, or other usual treatments. 
• Outcomes: including one or more of the outcomes of interest. 
o Primary outcomes  
▪ Muscle strength  
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o Secondary outcomes, including but not limited to the following outcomes 
and categories  
▪ Muscle mass 
▪ Molecular and cellular (e.g. muscle fibre type composition, insulin-
like growth factor 1 (IGF-1), immunohistochemical fibre denervation 
markers or satellite cells)  
▪ Function (e.g. gait speed or disability)  
▪ Hospital length of stay 
▪ Adverse effects (e.g. discomfort or pain) 
• Design: randomized controlled trials (RCTs) and quasi-randomized controlled trials. 
Exclusion criteria  
• Participants: patients selected due to psychiatric conditions, speech, swallowing or 
facial disorders.  
• Intervention: NMES not applied to a limb (e.g. solely applied to treat facial, swallow 
or speech problems). We will not include studies using electrical stimulation used 
for its afferent effect (such as for pain or spasticity) rather than to produce 
muscular stimulation, which will classify as transcutaneous elections stimulation 
(TENS). We will not include studies using pulsed electrical stimulation to augment 
normal movement such a functional electrical stimulation (FES).     
• Control: no control group, or comparisons only between different NMES 
parameters. 
• Reporting: not published in English. 
Information sources 
We will search the following electronic databases: MEDLINE, EMBASE, Cumulative Index 
to Nursing & Allied Health (CINAHL) and the Cochrane library.  
Search strategy 
The key words that will use to perform the search are: adults AND hospitalised AND 
critically ill AND neuromuscular electrical stimulation. The reference lists of the selected 
studies will be searched for additional studies. 
Study records: data management 
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Endnote 9 will be used to import research results and remove duplications. Results will 
then be transferred to Rayyan intelligent systematic review software for screening titles 
and abstracts, recording the reasons for exclusion, storing the full texts. 
Selection process 
Two reviewers will independently screen the titles and abstracts against the eligibility 
criteria. From those included at this stage, two reviewers will independently screen the 
full-text articles against the eligibility criteria. Any disagreements will be resolved by 
discussion or by a third reviewer. 
Data extraction 
Two reviewers will independently perform data extraction for all included studies by using 
a standardised data extraction table. The information extracted will include study 
information (first author, year of publication, country, design), participant characteristics 
(total sample size, gender, age, body mass index), intervention group (sample size, 
gender, age, detailed protocol parameters, additional intervention), control group (sample 
size, gender, age, intervention type), outcome measures, results. 
 
Risk of bias assessment 
Two reviewers independently will perform risk of bias assessments. The risk of bias for 
each study will be assessed using the Cochrane Collaboration risk of bias assessment tool 
for randomised trials [27] which takes account of: random sequence generation, allocation 
concealment, blinding of participants and personnel, blinding of outcome assessment, 
incomplete outcome data, selective reporting and other biases.  Each aspect will be graded 
as three levels; low, unclear, and high risk of bias. 
 
Quality assessment 
We will analyse the quality of the evidence available for each outcome of interest using 
the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool 
[28]. This will assess: study limitations/risk of bias, inconsistency of results, indirectness 
of evidence, imprecision and reporting bias. Then the quality of the evidence for each 
outcome will be classified as high, moderate, low or very low.  
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Data analysis and synthesis 
The nature and extent of the research evidence will be summarised using a standardised 
table, including: number of studies and patients, date, place, size, population, 
intervention, and outcome. If three or more studies with similar intervention investigate 
the same outcome domain using comparable measures, meta-analysis will be conducted. 
Review Manager (RevMan) software will be used. Mean difference or standardised mean 
difference, 95% confidence intervals and two-sided P values will be calculated to measure 
the treatment effect for each outcome. We will assess heterogeneity using the I2 statistic 
as the following: if the value of I2 less than 50% indicating acceptable heterogeneity, we 
will utilize a fixed-effect model. I2 greater than 50% means significant heterogeneity and 
we will use a random-effect model. 
If the criteria for meta-analysis are not met, a synthesis without meta-analysis (SWiM) 
will be conducted. The SWiM will take account of two elements: the quality of the evidence 
and the effect size. Each of the selective studies will be given a quality rating of low quality, 
moderate quality, and high quality depending on assessment of study quality.  
  Good quality: low risk of bias and sample size > 40 
  Moderate quality: high risk of bias and sample size > 40 
  Low quality: high risk of bias and sample size < 40 
The effect sizes (d) of each study and outcome will be calculated by the following equation 
(divide the difference between intervention group mean and control group mean by 
standard deviation), and then classified using Cohen’s classification whereby d < 0.2 “no 
effect”, d = 0.2-0.49 “small effect”, d = 0.5-0.79 “moderate effect”, and d ≥ 0.8 “large 
effect” [29].  
 
According to quality and effect size, we will interpret the result for each outcome to answer 
our research question by using the following classification 
• No evidence (no studies have examined this outcome)  
• Evidence of no effect (no effect showed by one or more studies of 
moderate or good quality) 
• Evidence of small effect (small effect showed by one or more studies of 
moderate or good quality) 
• Evidence of moderate effect (moderate effect showed by one or more 
studies of moderate or good quality) 
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• Evidence of large effect (large effect showed by one or more studies of 
moderate or good quality) 
• Inconsistent evidence (differing results and effect sizes between two or 
more studies of moderate or good quality) 
 
DISCUSSION 
Loss of muscle and disability is very common among hospitalised patients [1-3]. Previous 
studies suggested that NMES can preserve muscle mass and function. However, no 
systematic reviews investigated the effectiveness and safety of NMES in hospitalised 
patients. Therefore, this planned review will systematically explore the evidence of the 
effects of NMES in adults acutely admitted to hospital. The results of this study will supply 
high-quality evidence and recommendations for clinicians and scientific researchers. 
 
A potential limitation of this systematic review is that it will include only published trials 
and exclude unpublished data. However, although it has been suggested to include 
unpublished studies, the inclusion of these studies can introduce bias by itself. Further, 
unpublished studies are usually smaller and have poorer methodological quality than peer-
reviewed trials [30]. Another limitation is the reliance on English-language studies only. 
However, Morrison et al. [31] conclude that although English-language restriction may 
reduce the total amount of literature found, it does not introduce bias. We have anticipated 
the potential limitation that a numerical synthesis (meta-analysis) may not be possible for 
many or all the outcomes of interest due to different ways of measuring outcomes. 
Therefore, we have planneda synthesis without meta-analysis based upon the amount, 
quality and effect sizes found.  
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